The Venture Codex Logo

The Venture Codex

OurCrowd

28 Derech Hebron, Jerusalem, 9152101, Israel

Overview

OurCrowd is a venture investing platform that enables institutions and individuals to invest and engage in emerging companies. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global 'crowd' gains access to VC-level investment opportunities.

Total investments
203
Lead investments
47
Investments · 12mo
4
Active investors
9

Sector focus

  • Crowdfunding
  • FinTech
  • Funding Platform
  • Venture Capital
Visit website

Investment portfolio

  • Corgi

    Participated · Series B · May 2026

    Corgi is an AI-native, full-stack insurance carrier founded by Emily Yuan and Nico Laqua and headquartered in San Francisco. As a licensed carrier, it designs and manages insurance end-to-end and uses AI to power underwriting, policy management, and claims operations. The company launched its platform after receiving regulatory approval in July 2025 and initially focused on property-management insurance for startups. Corgi plans to expand its product suite into new verticals including trucking, payroll, and small-business insurance while broadening coverage and distribution. Financially, Corgi has raised over $268 million to date, including a $160 million Series B at a $1.3 billion valuation. The company is investing the new capital in AI systems, faster quoting, adaptive risk models, and operational scaling to support its growth plans.

  • Tevel

    Participated · Series C · Mar 2026

    Tevel develops flying autonomous robots and drone harvesting systems that pick fruit without human intervention. Its technology is described as ‘Physical AI’ aimed at automating harvesting to alleviate labour shortages and improve supply‑chain efficiency. Tevel is already working with commercial fruit producers, including Unifrutti in Chile and HMC Farms in California. The company raised $18 million in a Series C to accelerate deployment of its systems. Tevel plans to scale its operations and expand deployments in orchards and plantations globally. The article did not disclose revenue, user counts, or a valuation.

  • Winn

    Participated · Series A · Feb 2026

    Founded in 2022, Tel Aviv–based WINN.AI offers a real-time revenue execution platform that coaches sales representatives live on calls while automatically updating CRM and BI systems. The software standardizes best practices across large teams, freeing reps to focus on relationship building while AI handles data capture and process compliance. Since launching in June 2023, the company has secured notable enterprise customers such as Deel, Cyera, and Kaseya, reporting a 33% lift in win rates, a 2× CRM fill rate, and a 98% reduction in admin time in separate case studies. Operational traction has been strong: the company tripled annual recurring revenue in 2025, expanded ARR 30× over the past two years, and maintained 0% churn among enterprise accounts. WINN.AI integrates seamlessly with major CRMs, positioning itself as a core system rather than an add-on. Proceeds from its recent funding will support continued product development and expansion into the U.S. market. Management believes the shift from post-call analytics to proactive, in-call guidance represents a transformative opportunity in sales technology.

  • Omnix Medical

    Participated · Series C · Oct 2025

    Founded in 2015, Omnix Medical is focused on discovering and developing novel antimicrobial peptide (AMP) therapies that address life-threatening, antibiotic-resistant infections. Its lead candidate, OMN6, rapidly destroys bacterial cell membranes and has received Fast-Track and Qualified Infectious Disease Product designations from the U.S. FDA. The company is currently running Phase II proof-of-concept trials targeting Gram-negative pathogens such as Acinetobacter baumannii, a major cause of hospital-acquired infections. Proceeds from recent funding will also support regulatory preparations, manufacturing scale-up, and advancement of additional AMP candidates in the pipeline. Unlike traditional antibiotics that target specific bacterial functions, OMN6’s pore-forming mechanism minimizes the chance of resistance development. Since inception, Omnix Medical has raised a total of $43 million to finance its R&D and clinical programs.

  • Lidwave

    Participated · Seed · Oct 2024

    Lidwave develops 4D LiDAR-on-chip sensors built around its proprietary Finite Coherent Ranging (FCR™) technology, integrating lasers, amplifiers, receivers and optical routing onto a single chip. The company’s coherent sensing method provides pixel-level Doppler (velocity) data alongside depth information. Lidwave plans to further develop its optical chip and launch what it calls the industry’s first software-definable 4D LiDAR sensor. The technology is positioned to reduce the cost, complexity, and reliability issues associated with legacy LiDAR systems. Lidwave is collaborating with OEMs, Tier‑1 suppliers, and major players in industrial automation and smart infrastructure to drive adoption. The company says it will seek additional partnerships to scale production and extend its technology across industries to improve safety and automation.

Team

  • Jonathan Medved

    Founder, CEO

    LinkedIn
  • Steve Wishner

    Co-Founder, General Partner and Venture Partner

    LinkedIn
  • Sean Ickowicz

    Business Development, Australia

    LinkedIn
  • Shmuel Bornstein

    Director Portfolio Management

    LinkedIn